Two drugs for advanced HER2-positive breast cancer (Enhertu and Tukysa)

Med Lett Drugs Ther. 2020 Nov 16;62(1611):182-184.
No abstract available

Keywords: Enhertu; HER2; Herceptin; Herzuma; Kadcyla; Perjeta; Tukysa; Xeloda; ado-trastuzumab; adverse effects; breast cancer; capecitabine; dosage; drug interactions; efficacy; fam-trastuzumab deruxtecan; lactation; paclitaxel; pertuzumab; pregnancy; safety; trastuzumab; tucatinib.

MeSH terms

  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / genetics*
  • Camptothecin / analogs & derivatives*
  • Camptothecin / therapeutic use
  • Female
  • Humans
  • Immunoconjugates / therapeutic use*
  • Receptor, ErbB-2 / genetics*
  • Trastuzumab / therapeutic use*

Substances

  • Antineoplastic Agents
  • Immunoconjugates
  • trastuzumab deruxtecan
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab
  • Camptothecin